CYTK Q4 2025 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M+4.9% YoY

Gross Profit

$15M83.9% margin

Operating Income

-$178M-1004.6% margin

Net Income

-$183M-1030.9% margin

EPS (Diluted)

$-1.50

QoQ Revenue Growth

+817.1%

Cash Flow

Operating Cash Flow

-$143M

Free Cash Flow

-$148M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$2.1B

Stockholders' Equity

-$660M

Cash & Equivalents

$882M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$17M	+4.9%
Gross Profit	$15M	-$77M	+119.4%
Operating Income	-$178M	-$139M	-28.3%
Net Income	-$183M	-$150M	-22.0%

Revenue Segments

Collaboration Revenues

$4M100%

Geographic Segments

CHINA

$200,000100%